Sarepta疗法 SRPT 深 沪
已收盘 07-02 16:00:00 美东时间
19.28
+1.080
+5.93%
华盛通- 最 高19.56
- 今 开18.41
- 成交量 435.79万股
- 最 低 18.03
- 昨 收 18.20
- 总市值 20.36亿
- 52周最高 25.32
- 市盈率 静 --
- 换手率 4.13%
- 52周最低 10.415
- 委 比 -18.36%
- 总股本 1.06亿
- 历史最高 181.83
- 量 比 0.64
- 振 幅 8.41%
- 历史最低 0.433
- 每 手 1
- 风险率 2.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sarepta Therapeutics宣布根据纳斯达克上市规则5635(c)(4)授予激励性股权
纳斯达克上市的罕见病精准基因疗法企业Sarepta Therapeutics（股票代码SRPT）于2026年6月30日，向2026年第二季度入职的30名新员工授...
07-01 04:30
分析师精选医疗健康板块个股：Palisade Bio（PALI）、Sarepta Therapeutics（SRPT）
两名医疗板块分析师先后对Palisade生物（PALI）与Sarepta医疗（SRPT）给出看涨评级。 关键评级与数据： 马克西姆集团分析师纳兹·拉赫曼重申...
06-30 22:58
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027
– Accepted for review with target action date of February 28, 2027 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sN...
06-30 20:38
Sarepta Therapeutics 获FDA设定PDUFA目标审批日期为2027年2月28日
萨雷普塔疗法公司相关产品的美国食品药品监督管理局PDUFA目标审批日期已确定为2027年2月28日。 译文内容由第三方软件翻译。 声明：市场有风险，投资需谨慎...
06-30 20:37
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps leading the tape, as investors held their fire ahead of Kevin Warsh‘s first interest-rate decision as Federal Reserve chair, due at 2 p.m. ET. The Fed is all but certain to hold the funds rate at 3.50%-3...
06-18 01:33
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
The latest update is out from Sarepta Therapeutics ( ($SRPT) ). On June 4, 2026...
06-05 05:32
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
Sarepta Therapeutics Inc. ($SRPT) announced an update on their ongoing clinical...
06-05 00:34
UPDATE 1-Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion
UPDATE 1-Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion Adds shares in paragraph 2, analysts' comments in paragraphs 6,9,10 By Siddhi Mahatole June 1 (Reuters) - Edgewise Therapeutics EWTX.O said on Monday it would sell its experimental muscular dystrophy drug and rela
06-01 21:44
UPDATE 3-Replimune gets third chance at US approval for skin cancer drug
UPDATE 3-Replimune gets third chance at US approval for skin cancer drug Shares surge 77% after resubmission news FDA to prioritize review of resubmitted application, Replimune says BMO Capital analyst notes uncertainty over what prompted FDA's change in stance Adds analyst comment in paragraph 7, c
05-29 20:12
Capricor names Michael Maurer chief commercial officer
Capricor names Michael Maurer chief commercial officer Capricor Therapeutics appointed Michael Maurer as chief commercial officer, effective immediately, to strengthen launch readiness for Deramiocel in Duchenne muscular dystrophy. Maurer brings about two decades in rare-disease commercialization, p
05-29 09:58
